WilmerHale Reps Achillion Pharmaceuticals in Pricing of Secondary Offering of Common Stock

WilmerHale Reps Achillion Pharmaceuticals in Pricing of Secondary Offering of Common Stock

Firm News

Achillion Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc., which shares constitute all of JJDC's equity position in Achillion, at a public offering price of $2.75 per share. The offering is expected to close on November 20, 2017.

The WilmerHale deal team representing Achillion includes Steven Singer, Cynthia Mazareas, Scott Lunin and Killian Nolan.

Read Achillion's press release for more details.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.